These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8094849)

  • 1. Eltoprazine for aggression in mental handicap.
    Kohen D
    Lancet; 1993 Mar; 341(8845):628-9. PubMed ID: 8094849
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltoprazine for aggression in schizophrenia and mental retardation.
    Tiihonen J; Hakola P; Paanila J; Turtiainen M
    Lancet; 1993 Jan; 341(8840):307. PubMed ID: 8093942
    [No Abstract]   [Full Text] [Related]  

  • 3. Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study. The Eltoprazine Aggression Research Group.
    de Koning P; Mak M; de Vries MH; Allsopp LF; Stevens RB; Verbruggen R; Van den Borre R; van Peteghem P; Kohen D; Arumainayagam M
    Int Clin Psychopharmacol; 1994 Sep; 9(3):187-94. PubMed ID: 7814828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive action, in contrast to haloperidol.
    Mos J; van Aken HH; van Oorschot R; Olivier B
    Eur Neuropsychopharmacol; 1996 Mar; 6(1):1-7. PubMed ID: 8866931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Carta M; Cenci MA
    Mov Disord; 2016 Jan; 31(1):149. PubMed ID: 26749366
    [No Abstract]   [Full Text] [Related]  

  • 6. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF; Lesourd M; Mocaer E; Koolhaas JM
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenics.
    Olivier B; Mos J; Raghoebar M; de Koning P; Mak M
    Prog Drug Res; 1994; 42():167-308. PubMed ID: 8085010
    [No Abstract]   [Full Text] [Related]  

  • 10. Eltoprazine suppresses hyperpolarizing responses to serotonin in rat hippocampus.
    Joëls M; Pennartz CM; Sijbesma H; Schipper J
    J Pharmacol Exp Ther; 1990 Apr; 253(1):284-9. PubMed ID: 2329512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of eltoprazine.
    Wigal SB; Duong S
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):775-81. PubMed ID: 21548716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Drug holiday' effects of tandospirone in a patient with Machado-Joseph disease.
    Takei A; Fukazawa T; Hamada T; Yabe I; Tashiro K
    Psychiatry Clin Neurosci; 2003 Dec; 57(6):607-8. PubMed ID: 14629711
    [No Abstract]   [Full Text] [Related]  

  • 13. Paroxetine-induced bruxism effectively treated with tandospirone.
    Kishi Y
    J Neuropsychiatry Clin Neurosci; 2007; 19(1):90-1. PubMed ID: 17308240
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged marijuana-like dysphoria after subcutaneous sumatriptan.
    Bakshi R; Yan-Go FL
    Ann Pharmacother; 1996 Jun; 30(6):683. PubMed ID: 8792959
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of eltoprazine hydrochloride on reactivity to conspecific or novel odors and activity.
    Ostrem JL; Rawleigh JM; Kemble ED
    Pharmacol Biochem Behav; 1992 Mar; 41(3):581-5. PubMed ID: 1584837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
    Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
    Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craving for cocaine in addicted users. Role of serotonergic mechanisms.
    Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
    Am J Addict; 1997; 6(1):65-73. PubMed ID: 9097873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rating aggression in the clinical setting. A retrospective adaptation of the Overt Aggression Scale: preliminary results.
    Sorgi P; Ratey J; Knoedler DW; Markert RJ; Reichman M
    J Neuropsychiatry Clin Neurosci; 1991; 3(2):S52-6. PubMed ID: 1687961
    [No Abstract]   [Full Text] [Related]  

  • 20. Buspirone for the treatment of dementia with behavioral disturbance.
    Santa Cruz MR; Hidalgo PC; Lee MS; Thomas CW; Holroyd S
    Int Psychogeriatr; 2017 May; 29(5):859-862. PubMed ID: 28124634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.